Oncodesign is engaged and committed to help finding preventing & therapeutic solutions against infectious diseases such as pandemic Covid-19 disease

UK, Brazilian and South-African SARS-CoV-2 variants now available for preclinical studies


Test in vitro and in vivo your therapeutic approaches

Oncodesign continually brings adapted preclinical solutions in light of the COVID-19 context and evolution. 


A whole battery of in vitro & in vivo models, including imaging studies in infected Non Human Primate

Oncodesign and its strategic partner* offer straightforward, immediately available or shortly validated in vitro & in vivo models based of a broad number of readouts.

In our commitment to fight against Covid19 pandemia, Oncodesign has now access to newly isolated SARS-CoV-2 variants for preclinical therapeutic testing:

- UK variant (known as 20I/501Y.V1 or B.1.1.7) with the N501Y, P681H and 69/70 del mutations
- South African variant (known as 20H/501Y.V2 or B.1.351) with the K417N, E484K and N501Y mutations
- Brazilian variant (known as 20J/501Y.V3 or B.1.1.248) bearing 17 unique mutations, including K417T, E484K, and N501Y.

Here are our preclinical models to support your drug development.


Golden Syrian Hamster

- Airways & lung inflammation with diffuse alveolar damage
- Viral antigens in bronchial epithelial cells, pneumocytes, alveolar macrophages
- Clinical manifestations associated with weight loss peaking
- Lymphoid atrophy associated with marked innate immune cell activation
- Neutralizing antibodies detection

Non human Primate Monkey

- Induction of a COVID-19-like disease
- Prolonged excretion of virus from nose & throat
- Pulmonary lesions characterized by CT & PET-CT
- Seroconversion
- Early inflammatory response
- Low fever

Preventing & therapeutics solution - COVID-19-2

Invalid Input

Invalid Input

Invalid Input

your address is not a proper one. Please check.

Invalid Input

We care about your privacy.
Since you are a valuable customer or prospect, we want to make sure that you can choose to stay connected with Oncodesign. Oncodesign collectgs your data to provide you with information regarding our offering and news.
In accordance with the law "Informatique et Libertés", you can exercise your right of access to the data concerning you and have them rectified by contacting odsmarketing@oncodesign.com.
Your Email address has not been and will not be given to third parties. 

Oncodesign is registered with CNIL under number 2102182.


 Biochemical assay banner

- Binding assays on viral Spike S
- Binding assays on human ACE2 proteins
- TMPRSS2 (Type II transmembrane serine protease)

TMPRSS2 mechanism

cell assay banner

- Sars-CoV-2 infected cells Human (lung, intestine, broncho-alveolar)
  Monkey (kidney)
- Viral load
- Cytopathogenic effect
- Immune modulation
- Air-liquid interface

Cell testing


COVID-19 patients may progress to Acute Respiratory Distress Syndrome (ARDS), of which a subset of survivors will develops lung fibrosis. Potential of shared mechanisms between post-ARDS fibrosis and chronic Interstitial Lung Diseases raises the hypothesis that ILDs therapies could also be beneficial for COVID-19 associated lung disease.

Within this framework, Oncodesign has a validated Bleomycin induced pulmonary fibrosis model in C57BL/6 mice.

Additionally, early research indicate that many of the fatal cases of COVID-19 result from over-activation of a person’s immune system, referred to as a “cytokine storm”, could be key in preventing the virus deadly effects.

Once released, the cytokines trigger localised inflammation. Understanding which cytokines are released in response to infection can be as important as knowing the quantities of cytokines released.

To investigate number of strategies, both repurposing and new ones, Oncodesign can assess the reduction of activation of immune cells by assessing cytokine production or specific signaling pathways dependent on pro-inflammatory cytokines.

Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome (ARDS)

Cytokine Storm

Cytokine Storm

Feed me with your innovative solutions to fight COVID-19

Our expert teams are available to discuss your projects to find the best of our options to assess either your preventing or therapeutics solution with either off-the-shelf tools or customized ones!

*Our Partner IDMIT

Oncodesign is a founding member of IDMIT (Infectious Disease Models and Innovative Therapies), a national French research infrastructure. IDMIT is a world-class research infrastructure dedicated to preclinical research to study and understand infectious diseases and to develop and evaluate innovative preventive and therapeutic strategies.

The aim of this infrastructure is to develop animal models of human infections, centralize state-of-the-art technological platforms, particularly in in vivo imaging, and provide a highly competitive infrastructure for preclinical research on vaccines and anti-infectious treatments. IDMIT has models of human viral infections in non-human primates, in particular for the study of HIV/AIDS, Corona Virus, Dengue, Chikungunya, influenza, yellow fever, etc.